DarioHealth Corp. (DRIO)

In November 2025, DarioHealth reported Q3 financial results, presented data at ISPOR Europe 2025, and a Sanofi study showed medical cost savings. In October 2025, DarioHealth filed to sell shares of common stock. In September 2025, DarioHealth announced a strategic review, a private placement of common stock, a reverse stock split, a shareholder update, and new employer contracts. In August 2025, DarioHealth reported Q2 financial results and set a special dividend date.

The provided information does not explicitly indicate any significant demand seasonality for DarioHealth Corp.'s products and services. The company's focus on managing chronic conditions and its shift to a B2B2C model with recurring revenues suggest a more consistent demand driven by ongoing healthcare needs rather than seasonal fluctuations.

DarioHealth Corp. is a global digital therapeutics company operating in the Health Technology sector, providing personalized interventions for chronic conditions through its platform and suite of solutions. Key products and services include the Dario Blood Glucose Monitoring Starter Kit, the Dario Blood Pressure Monitoring System, a multi-chronic condition digital therapeutics platform, Dario Connect, and Dario Mind.

DarioHealth Corp. has a global presence with offices in New York, United States, and Israel. The company's digital health solutions serve customers in six countries, including the United States, Canada, the European Union, Australia, and New Zealand.

DarioHealth has solidified its reputation as a premier platform in the B2B2C market. The acquisition of Twill Inc. strengthened its leadership, clinical validation and cost savings were demonstrated, it leads with a multi-condition platform, experiences strong client growth and retention, and leverages AI-powered solutions.

DarioHealth Corp.'s ownership includes institutional investors (18.41% to 28.09%), individual/public investors (significant portion, with retail investors owning approximately 44.96% and individuals accounting for 17.9% of the 1000 largest holdings), and insiders (26.95%), with CEO Erez Raphael being a significant individual shareholder.